Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______. Commission File Number: 001-34632 CRYOPORT, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 88-0313393 ...

Cryoport, Inc. (NASDAQ:CYRX) Q2 2021 Earnings Conference Call August 5, 2021 5:00 PM ET Executives Todd Fromer - Managing Partner-KCSA Jerrell Shelton - Chairman, President and Chief Executive Officer Robert Stefanovich - Chief Financial Officer, Treasurer and Corporate Secretary Mark Sawicki - Chief Scientific Officer Thomas Heinzen - Vice President-Corporate Development & Investor Relations Analysts Matt Andrews - Jefferies Andrew D'Silva - B. Riley Securities David Larsen - BTIG Jacob Johnson - Stephens ...

Table of Contents Title of each class: Trading Symbol(s) Name of each exchange on which registered: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______. Commission File Number: 001-34632 CRYOPORT, ...

Market Growth and Trends - The global cell and gene therapy (C&GT) market was valued at approximately $4.2 billion in 2019 and is projected to grow to over $33.1 billion by 2024[210]. - The biopharma/pharma market has over 1,200 global clinical trials underway in 2021, highlighting the growing demand for temperature-controlled supply chain solutions[228]. Company Performance and Financials - Total revenues increased by $43.5 million, or 445.2%, from $9.8 million to $53.3 million for the three months ended March 31, 2021, compared to the same period in 2020[236]. - Service revenues rose by $17.0 million, or 173.8%, from $9.8 million to $26.8 million for the three months ended March 31, 2021, driven by the acquisition of CRYOPDP[237]. - Product revenues were $26.5 million for the three months ended March 31, 2021, primarily due to the acquisition of MVE Biological Solutions[238]. - Revenue from the biopharma/pharma market increased by $33.6 million, or 382.5%, from $8.8 million to $42.4 million for the three months ended March 31, 2021[240]. - Revenues in the reproductive medicine market increased by $1.1 million, or 148.4%, from $0.8 million to $1.9 million for the three months ended March 31, 2021[242]. - Gross margin for the three months ended March 31, 2021, was 46.1% of total revenues, compared to 53.8% for the same period in 2020[243]. - Organic revenue increased by $3.5 million, or 35.3%, to $13.2 million for the three months ended March 31, 2021[236]. - Adjusted EBITDA for the three months ended March 31, 2021, was $6.978 million, compared to a loss of $1.770 million in the same period in 2020[258]. Operational Developments - As of the end of Q1 2021, the company supported 543 clinical trials and seven commercial therapies, with expectations for up to 21 additional C&GTs to file for regulatory approval in 2021[211]. - The number of clinical trials supported increased to 543, with 69 Phase III trials as of March 31, 2021[240]. - The company expanded its global presence to a network of 27 supply chain centers in 13 countries following the acquisition of CRYOPDP in October 2020[224]. - The acquisition of MVE Biological Solutions enhances the company's capabilities in cryobiological storage and transportation, securing supply for the growing C&GT market[225]. - The company has established strategic alliances with major logistics providers, including FedEx, DHL, and UPS, to integrate advanced cryogenic logistics solutions[215]. - The Cryoportal Logistics Management Platform provides comprehensive shipment management, including near real-time tracking and regulatory compliance[220]. - The Chain of Compliance® solution introduced in 2018 sets a new industry standard for traceability in the C&GT market[221]. - The company is focused on continuous innovation to develop products that address unmet needs in the global supply chain of the C&GT market[213]. Expenses and Financial Management - Selling, general and administrative expenses increased by $14.3 million, or 200.7%, compared to the first quarter of 2020, primarily due to acquisitions[247]. - Engineering and development expenses increased by $2.6 million, or 148.4%, for the three months ended March 31, 2021, compared to the same period in 2020, primarily due to consulting and development costs[249]. - Interest expense rose by $1.2 million for the three months ended March 31, 2021, compared to the same period in 2020, attributed to interest on convertible senior notes[250]. - The provision for income taxes increased by $1.0 million for the three months ended March 31, 2021, with an effective tax rate of negative 41.7% for U.S. earnings[252]. Cash Flow and Capital Management - As of March 31, 2021, the company had cash and cash equivalents of $85.5 million and short-term investments of $267.7 million, with working capital of $381.9 million[259]. - Net cash used in investing activities was $215.4 million during the three months ended March 31, 2021, primarily due to the purchase of short-term investments[261]. - Net cash provided by financing activities totaled $271.4 million during the three months ended March 31, 2021, mainly from net proceeds of $269.8 million from a public offering[262]. - The company recognizes potential need for additional capital to fund operations and acquisitions until sustained profitable operations are achieved[263]. - Foreign exchange risk related to cash and cash equivalents as of March 31, 2021, indicates that a 5%, 10%, and 20% adverse change would result in declines of $0.8 million, $1.5 million, and $3.1 million, respectively[268]. Impact of COVID-19 - The company continues to monitor the evolving situation caused by the COVID-19 pandemic, which has temporarily impacted revenue growth[234].

Cryoport, Inc. (NASDAQ:CYRX) Q1 2021 Results Conference Call May 4, 2021 5:00 PM ET Company Participants Todd Fromer - Managing Partner, KCSA Jerrell Shelton - CEO Robert Stefanovich - CFO Dr. Mark Sawicki - Chief Scientific Officer Thomas Heinzen - VP, Corporate Development and IR Conference Call Participants Matt Andrews - Jefferies Andrew D’Silva - B. Riley Paul Knight - KeyBanc David Saxon - Needham John Sourbeer - UBS Richard Baldry - ROTH Capital Partners Operator Thank you for standing by. This is th ...

Cryoport, Inc. (NASDAQ:CYRX) Q4 2020 Earnings Conference Call March 1, 2021 5:00 PM ET Company Participants Todd Fromer - Managing Partner, KCSA Jerrell Shelton - Chief Executive Officer Robert Stefanovich - Chief Financial Officer Mark Sawicki - Chief Scientific Officer Thomas Heinzen - Vice President, Corporate Development & Investor Relations Conference Call Participants Puneet Souda - SVB Leerink Brandon Couillard - Jefferies Andrew D'Silva - B. Riley Securities Richard Baldry - ROTH Capital David Saxon ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-34632 CRYOPORT, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 88-0313393 (State or other juris ...

Cryoport, Inc. (NASDAQ:CYRX) Q3 2020 Earnings Conference Call November 5, 2020 5:00 PM ET Company Participants Todd Fromer - Managing Partner, KCSA Jerrell Shelton - Chief Executive Officer Robert Stefanovich - Chief Financial Officer Mark Sawicki - Chief Scientific Officer Thomas Heinzen - Vice President, Corporate Development & Investor Relations Conference Call Participants Andrew D'Silva - B. Riley Securities Joseph Conway - Needham & Company Operator Good day everyone, and welcome to the Cryoport Incor ...

Revenue Growth - Cryoport reported Q3 2020 revenue of $122 million from Novartis's KYMRIAH® compared to $79 million for Q3 2019, reflecting a 54% year-over-year increase[220]. - Kite Pharmaceuticals generated $138 million in Q3 2020 revenue from YESCARTA®, down from $156 million in Q2 2020[221]. - Revenues increased by $1.6 million or 16.6% to $11.2 million for the three months ended September 30, 2020, compared to $9.6 million for the same period in 2019[234]. - Biopharmaceutical revenue rose by $953,200 or 12.8% to $8.4 million, driven by an increase in the number of biopharmaceutical customers and clinical trials supported[235]. - Revenues increased by $5.6 million or 22.8% to $30.3 million for the nine months ended September 30, 2020, driven by increased biopharmaceutical customer utilization and clinical trials supported[244]. - Biopharmaceutical revenue rose by $3.2 million or 15.7% to $23.2 million for the nine months ended September 30, 2020, with 84 new biopharma clients added[244]. Client and Trial Expansion - As of September 30, 2020, Novartis has qualified 260 treatment centers in over 26 countries for KYMRIAH®[220]. - Kite Pharmaceuticals had 180 certified centers authorized to treat patients globally as of Q3 2020[221]. - The company added approximately 34 new biopharma clients and 26 clinical trials during the three months ended September 30, 2020, bringing the total to 517 clinical trials[235]. - The number of clinical trials supported increased to 517 as of September 30, 2020, compared to 425 trials supported as of September 30, 2019[245]. Financial Performance - Gross margin improved to 54.2% of revenues for the three months ended September 30, 2020, up from 48.3% in the same period in 2019[238]. - Gross margin improved to 54.2% of revenues for the nine months ended September 30, 2020, up from 50.3% in the same period in 2019, due to increased business volume and pricing adjustments[248]. - The net loss for the three months ended September 30, 2020, was $11.4 million, a decrease of $1.1 million or 8.4% compared to the net loss of $12.5 million in the same period in 2019[234]. - General and administrative expenses increased by $1.4 million or 15.1% due to consulting and legal services related to strategic initiatives and increased employee costs[239]. - General and administrative expenses rose by $5.2 million or 34.1% for the nine months ended September 30, 2020, primarily due to consulting and legal services related to strategic initiatives[249]. - Interest expense increased by $561,200 for the nine months ended September 30, 2020, due to the issuance of 3% senior convertible notes in May 2020[252]. Operational Developments - Cryoport's acquisition of Cryogene expanded its biostorage capabilities, providing a cGMP compliant temperature-controlled sample management solution from a 21,000 square foot facility in Houston, Texas[213]. - The company supports three largest integrators globally, including FedEx, DHL, and UPS, enhancing its logistics solutions for the life sciences industry[215]. - Cryoport's Advanced Therapy Shippers™ were launched to ensure traceability and minimize contamination risks for human-based therapies[212]. - Cryoport's logistics management platform, Cryoportal®, provides real-time monitoring and compliance documentation for shipments[211]. - The company aims to redefine logistics in life sciences by integrating temperature-controlled logistics, bioservices, and end-product fulfillment[218]. - Bluebird bio is expected to treat its first commercial patients in Germany in Q4 2020, supported by Cryoport's logistics solutions[222]. Market Performance - Revenues in the reproductive medicine market surged by $453,300 or 61.6% to $1.2 million, attributed to the resumption of operations in fertility clinics[236]. - Global Bioservices revenue increased by $178,500 or 15.3% to $1.3 million, driven by new client onboarding[236]. - Global Bioservices revenue was $3.9 million for the first nine months of 2020, attributed to the acquisition of the Cryogene business in May 2019[246]. - Cost of revenues rose by $160,600 or 3.2% to $5.1 million, mainly due to increased freight charges from higher shipment volumes[238]. Cash Position - The company had cash and cash equivalents of $162.0 million and $41.0 million in short-term investments as of September 30, 2020[254]. - Net cash provided by financing activities totaled $119.1 million during the nine months ended September 30, 2020, primarily from the issuance of convertible senior notes[259]. Expense Management - Sales and marketing expenses decreased by $2.3 million or 38.2%, primarily due to a reduction in stock compensation expense[240]. - Engineering and development expenses increased by $3.3 million or 124.3% for the nine months ended September 30, 2020, compared to the same period in 2019, primarily due to a $3.1 million increase in consulting expenses[251].

Revenue Growth - Cryoport reported Q2 2020 revenue of $118 million from Novartis's KYMRIAH® compared to $58 million for Q2 2019, indicating a 103% year-over-year increase[195]. - Kite Pharmaceuticals reported Q1 2020 revenue of $140 million from YESCARTA® compared to $96 million for Q1 2019, reflecting a 46% increase[196]. - Revenues increased by $925,400 or 10.9% to $9.4 million for the three months ended June 30, 2020, compared to $8.5 million for the same period in 2019[210]. - Revenues increased by $4.0 million or 26.8% to $19.1 million for the six months ended June 30, 2020, compared to $15.1 million for the same period in 2019[221]. Biopharmaceutical Revenue - Biopharmaceutical revenue rose by $324,800 or 4.7% to $7.3 million, driven by an increase in the number of biopharmaceutical customers and clinical trials supported[212]. - Biopharmaceutical revenue rose by $2.2 million or 17.5% to $14.8 million, driven by an increase in the number of biopharmaceutical customers and clinical trials supported[221]. Clinical Trials and Clients - The company added approximately 12 new biopharma clients and 26 clinical trials during the three months ended June 30, 2020[210]. - The number of clinical trials supported increased to 491 as of June 30, 2020, compared to 413 as of June 30, 2019[212]. - The company added approximately 45 new biopharma clients and 55 clinical trials, increasing total supported clinical trials to 491 as of June 30, 2020[223]. Gross Margin - Gross margin improved to 54.6% of revenues for Q2 2020, up from 51.3% in Q2 2019, due to increased business volume and pricing adjustments[213]. - Gross margin improved to 54.2% of revenues for the six months ended June 30, 2020, up from 51.5% in the same period in 2019[224]. Expenses - General and administrative expenses surged by $2.5 million or 75.9% for Q2 2020, primarily due to consulting and legal services for acquisition-related activities[214]. - General and administrative expenses increased by $3.8 million or 63.9% due to acquisition-related activities and increased employee costs[225]. - Engineering and development expenses increased by $1.4 million or 259.8% for Q2 2020, reflecting investments in enhancing logistics solutions[217]. - Engineering and development expenses surged by $2.6 million or 257.0%, primarily due to consulting expenses aimed at enhancing logistics solutions[227]. Cash and Financing - Cash and cash equivalents stood at $44.3 million, with total working capital of $207.2 million as of June 30, 2020[231]. - Net cash used in investing activities was $119.6 million, mainly due to the purchase of short-term investments and software development costs[233]. - Net cash provided by financing activities totaled $117.0 million, primarily from the issuance of convertible senior notes[234]. Strategic Alliances and Logistics - Cryoport's acquisition of Cryogene expanded its biostorage capabilities, providing a cGMP compliant temperature-controlled sample management solution from a 21,000 square foot facility in Houston, Texas[188]. - The company supports the three largest integrators in the world—FedEx, DHL, and UPS—with advanced cryogenic logistics solutions[190]. - Cryoport's Advanced Therapy Shippers™ are designed for human-based therapies, ensuring traceability and minimizing cross-contamination risks[187]. - Cryoport's logistics management platform, Cryoportal®, provides real-time monitoring and a fully documented history of shipments, enhancing regulatory compliance[186]. - The company has established strategic alliances with key players in the logistics and life sciences industries to enhance service integration[189]. - Cryoport's solutions are utilized for shipping and storage of various life sciences commodities, including CAR-T therapies, vaccines, and stem cells[194]. Future Outlook - The company anticipates continued growth driven by the acceleration of clinical trials and commercialization of regenerative medicine therapies globally[188]. - Interest expense rose by $64,300 for Q2 2020 due to the issuance of 3% convertible senior notes in May 2020[218]. - Other income, net increased by $371,300 for Q2 2020, driven by gains on equity securities and investment income[219].